Improving the Future of Healthcare through Transparent Discussions on Clinical Research and Practice
SINGAPORE and LONDON (PRWEB) October 29, 2018 -- Omics International is a leading flag-bearer of the open access movement, which publishes academic research including research on clinical trials and practice. From the 22nd of October to the 28th of October, 2018, Omics International celebrated the 10th International Open Access Week, themed- “designing equitable foundations for open knowledge.”
This theme is aimed at evaluating whether the open access movement has indeed brought about inclusivity to the field of scientific research and whether this movement has inadvertently brought about any inequities, if yes, then how can these inequities be rectified. This was an attempt at reassessing and redefining the end-points of the open access movement, in order to ensure that we are still in alignment with the original aims and objectives of the movement.
Clinical research and practice play a vital role in the introduction of new drugs to the market and improving health statistics by aiding in the development of new methods/strategies of detecting, and diagnosing disease conditions. According to one report, the global clinical trials market would reach USD 65.2 billion by the year 2025. The availability of the entire cassette of services right from drug discovery to post-marketing analytics has further simplified the field of clinical research, thereby bringing novel drugs to market with more rapidity.
One of the factors that significantly hamper the reach of the new drugs to the market is that clinical trials and the institutes/companies conducting the clinical research are subject to stringent regulatory requirements. Adhering to these myriad requirements poses a significant challenge for investigators, with any delays reflecting in the time cost and overall efficiency of a trial. A recent study reports that more than a third of clinical trials publishing intermediate findings fail to report the final results and that a fifth of clinical trial related articles change their conclusions prior to publication. Not only do such concealments allow for limited replication of the trial findings, but they may also have significant implications on the policies governing clinical research.
In such a scenario, the open-access format enhances the likelihood of influencing the decisions of policy-makers by demonstrating the significance of clinical findings to the taxpayers and allowing researchers a stepping stone to replicate the published data and validate the trial results. The fact that scientific content published in the open-access format can be translated into multiple languages without infringement of any copyright laws only makes it easier for people to access the results of clinical research from around the globe.
Omics publishes 51 clinical research related journals, which include prominent journals like- the Journal of Clinical Trials, Clinical Investigation, the Journal of Clinical Research & Bioethics, and the Journal of Clinical & Experimental Pharmacology.
In the spirit of the Open Access Week, Omics International had planned several activities for its authors, reviewers, Editors, and readers. Articles published during the open-access week not only garnered visibility for the authors, but were also be indicative of their solidarity with the open access movement. Dr. Srinubabu Gedela, the Founder and CEO of Omics International, had announced, special recognition for manuscripts submitted during the Open Access Week.
All the Editors, authors and reviewers shared their experiences of publishing in the open access format, making their own indelible contribution to the Open Access movement.
Abhishek Babu, PULSUS GROUP, http://www.pulsus.com, +91 4047482201, [email protected]
Share this article